Dianthus Therapeutics Inc. (DNTH)vsModerna Inc (MRNA)
DNTH
Dianthus Therapeutics Inc.
$92.48
+3.56%
HEALTHCARE · Cap: $5.03B
MRNA
Moderna Inc
$231.35
-6.97%
HEALTHCARE · Cap: $101.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 92799% more annual revenue ($2.52B vs $2.72M). DNTH leads profitability with a 0.0% profit margin vs -110.5%. DNTH earns a higher WallStSmart Score of 34/100 (F).
DNTH
Avoid34
out of 100
Grade: F
MRNA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.0%
Fair Value
$29.90
Current Price
$92.48
$62.58 premium
Margin of Safety
+73.1%
Fair Value
$150.76
Current Price
$231.35
$80.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 205.6% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Revenue surging 29.2% year-over-year
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -22.7% — below average capital efficiency
Trading at 13.7x book value
Weak financial health signals
ROE of -40.8% — below average capital efficiency
Earnings declined 85.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : DNTH
The strongest argument for DNTH centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 205.6% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.
Bear Case : DNTH
The primary concerns for DNTH are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
DNTH profiles as a hypergrowth stock while MRNA is a growth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.17 — expect wider price swings.
DNTH is growing revenue faster at 205.6% — sustainability is the question.
DNTH generates stronger free cash flow (-51M), providing more financial flexibility.
Bottom Line
DNTH scores higher overall (34/100 vs 31/100) and 205.6% revenue growth. MRNA offers better value entry with a 73.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dianthus Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?